Adding I-125 seed implantation curbs mortality in hepatocellular carcinoma patients with MPVTTJune 24, 2021Hepatocellular Carcinoma
Expanded living donor liver transplant criteria improves HCC outcomesJune 24, 2021Hepatocellular Carcinoma
Hydrogel spacers show safety and efficacy in phase II prostate cancer studyJune 24, 2021Hepatocellular Carcinoma
Low-dose-rate brachytherapy remains feasible for prostate cancer patients with median lobe hyperplasia. June 24, 2021Hepatocellular Carcinoma
Cognitive function remains a concern with ADT treatment for prostate cancerJune 24, 2021Hepatocellular Carcinoma
Transgluteal CT biopsy succeeds in detecting prostate cancer lesionsJune 24, 2021Hepatocellular Carcinoma
High-dose-rate brachytherapy proves effectiveness for lower risk prostate cancerJune 24, 2021Hepatocellular Carcinoma
Immune checkpoint protein predicts poor prostate cancer outcomesJune 24, 2021Hepatocellular Carcinoma
Functional outcomes, not complications, impact quality of life after prostate cancer surgeryJune 24, 2021Hepatocellular Carcinoma
MicroRNA risk model beats PSA and Gleason scores in prostate cancer prognosisJune 24, 2021Hepatocellular Carcinoma
MicroRNA risk model beats PSA and Gleason scores in prostate cancer prognosisJune 24, 2021Hepatocellular Carcinoma
Grade group 4 biopsy shows potential predictive value for prostate cancerJune 24, 2021Hepatocellular Carcinoma
